5 results about "Non allergic" patented technology

This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions.

The application discloses a combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and a construction method and application of a model thereof. The combination of intestinal microbial functional markers for diagnosing allergic risk of infants and young children and the kit thereof can accurately and efficiently diagnose the microecological allergic risk of infants and young children of different ages. By integrating multi-dimensional characteristics such as functional gene abundance and KEGG metabolic pathway function activity level, the model can reveal the core mechanism of affecting the host immunity from the perspective of the function of the flora, thereby improving the prediction efficiency and enhancing the biological interpretability of the model. The AUC of the method reaches 0.84 on the test set, indicating that the method has good ability to distinguish allergic and non-allergic individuals. The models of different age groups all have high consistency, proving that the method is stable and reliable and can meet the accuracy requirements of clinical auxiliary decision-making.

The present invention relates to iota-carrageenan for use as a main or sole active ingredient in an aqueous pharmaceutical composition for the prevention or treatment of non-viral non-allergic clinically relevant eye conditions affecting at least one of mucosal tissues at or around an individual's eye, an eye surface, corneal tissue, and fluid inside the eye, said clinically relevant eye conditions selected from the group consisting of increased intraocular pressure, non- allergic and non-viral conjunctivitis, irritations caused by airborne particulate matter other than allergens, and late complications of non-viral and non-allergic conjunctivitis selected from the group consisting of corneal opacities, subepithelial infiltrates, and formation of ocular pseudomembranes.

The present invention refers to the medical field. Particularly, the present invention refers to an in vitro method for the diagnosis of allergic asthma or nonallergic asthma in a subject suffering from asthma, or for the differential diagnosis of allergic asthma and nonallergic asthma in a subject suffering from asthma, or for the prognosis of asthma in a subject suffering from asthma, which comprises assessing the expression level of the LGALS3 gene in a biological sample obtained from the subject. It also refers to the in vitro use of the expression level of the LGALS3 gene, or in vitro use of a kit comprising reagents for the same purposes.

The present disclosure is related to antibodies (e.g., human antibodies) and antigen-binding fragments thereof that specifically bind and neutralize (human) thymic stromal lymphopoietin (TSLP). Such molecules may have modified Fc regions that increase antibody half-life, increase resistance to proteases, and / or reduce ability to interact with Fc gamma receptors. These molecules are useful for treatment of allergic and non-allergic inflammation associated with TSLP-related disorders and diseases.